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The vast majority of currently licensed human vac-
cines work on the basis of long-term protective anti-
body responses. It is now conceivable that an
antibody-dependent HIV vaccine might be possible,
given the discovery of HIV broadly neutralizing anti-
bodies (bnAbs) in some HIV-infected individuals.
However, these antibodies are difficult to develop
and have characteristics indicative of a high degree
of affinity maturation in germinal centers (GCs).
CD4+ T follicular helper (Tfh) cells are specialized
for B cell help and necessary for GCs. Therefore,
the development of HIV bnAbs might depend on
Tfh cells. Here, we identified in normal individuals a
subpopulation of circulating memory PD-1+CXCR5+
CD4+ T cells that are resting memory cells most
related to bona fide GC Tfh cells by gene expression
profile, cytokine profile, and functional properties.
Importantly, the frequency of these cells correlated
with the development of bnAbs against HIV in a large
cohort of HIV+ individuals.
INTRODUCTION
Most human vaccines currently in use rely on the generation of
protective, long-lasting antibody responses (Plotkin, 2010). T
follicular helper (Tfh) cells are CD4+ T cells specialized in
providing help to B cells, particularly within germinal centers
(GCs), which are distinct structures in secondary lymphoid
organs. Tfh cells support B cell differentiation into affinity-
matured long-lived plasma cells and memory B cells by coloc-
alizing with B cells and delivering signals via costimulatory758 Immunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc.molecules and lymphokines (CD40L, interleukin-21 [IL-21],
IL-4, and CXCL13) that constitute the functional signature of
this specific CD4+ T cell subset (Crotty, 2011). Furthermore,
Tfh cells are needed for the crucial affinity-maturation process
of B cells in GCs, whereby antigen-specific B cells undergo
repeated rounds of somatic hypermutation and positive selec-
tion by Tfh cells to rapidly evolve high-affinity somatically
mutated B cell receptors (BCRs) (Crotty, 2011; Victora and Nus-
senzweig, 2012); this results in the development of memory B
cells and plasma cells with greater protective efficacy. In addi-
tion to being necessary for GCs, Tfh cells are also frequently
limiting for the magnitude of GCs and antibody responses
(Johnston et al., 2009; Rolf et al., 2010; Victora et al., 2010).
Therefore, there is widespread interest in manipulating Tfh cells
for vaccine enhancement.
Because of their necessary role in the generation of protective
T-cell-dependent antibody responses, there is substantial
potential for an understanding of Tfh cells to facilitate better
long-term antibody responses for vaccines. One case of great
importance is the generation of HIV broadly neutralizing anti-
bodies (bnAbs) in humans. Seminal studies in the past few years
have shown that 5% or more of HIV+ individuals are able to
develop highly potent bnAbs (Kwong and Mascola, 2012). HIV
bnAbs that can neutralize 70% or more of globally circulating
HIV strains (Huang et al., 2012; Scheid et al., 2011; Walker
et al., 2011; 2009) and can prevent infection in passive-transfer
experiments using non-human primates (Moldt et al., 2012)
have been characterized. Therefore, a vaccine eliciting such an-
tibodies might have the ability to protect immunized individuals
from HIV infection (Burton et al., 2012; McMichael and Haynes,
2012). Although this is an extremely important and interesting
potential HIV vaccine strategy, little is known about the cellular
mechanisms involved in generating HIV bnAbs. One hypothesis
is that Tfh cells are important for the development of HIV bnAbs
because of the extensive somatic hypermutation observed in the
vast majority of HIV bnAbs (Streeck et al., 2013).
Figure 1. Blood Total CXCR5+CD4+ T Cells
Fail to Correlate with HIV bnAb Develop-
ment
(A) Categorization of 328 HIV+ individuals enrolled
in the IAVI Protocol C cohort by HIV-neutralizing
ability of serum (upper panel: top neutralizers, red;
intermediate neutralizers, yellow; and low neu-
tralizers, blue). The number of HIV viruses
neutralized, of a cross-clade panel (of six total
viruses), at either >40% or >50% at a 1/100 serum
dilution for top and low neutralizing groups is
shown for each individual donor. ‘‘Score’’ in-
dicates the overall bnAb score (lower panel). ‘‘V’’
stands for virus neutralization.
(B) Representative frequency of blood CD4+
CXCR5+ cells (gated on CD45RO+CD4+ T cells).
(C) A representative flow cytometry plot of an HIV+
donor shows the gate for total CXCR5+CD4+
T cells (gated on CD3+CD4+ live cells).
(D) The percentage of CXCR5+CD4+ T cells in HIV
and HIV+ groups. Blood samples were from the
earliest available time point (4 months) after HIV
infection, years before the development of bnAbs.
‘‘Top’’ indicates the top neutralizers, and ‘‘low’’
indicates the low neutralizers. Each point repre-
sents an individual donor. Mean and SEM are
shown for each group. ‘‘ns’’ stands for not signif-
icant.
Also see Figure S1.
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Tfh Cells Correlate with HIV AntibodiesHere, we describe a subset of blood-circulating memory
CXCR5+CD4+ T cells that are characterized by stable and mod-
erate expression of the Tfh cell marker PD-1 (PD-1+CXCR5+
cells) and that most resemble GC Tfh cells among resting mem-
ory CD4+ T cells in terms of B cell help functionality and tran-
scriptional signature. Strikingly, a highly functional PD-1+
CXCR3CXCR5+CD4+ T cell population is overrepresented in
rare individuals who generate bnAbs against HIV.
RESULTS
Total CXCR5+CD4+ T Cells in Blood Fail to Correlate
with bnAb Production in HIV+ Donors
Among HIV+ individuals, only a minority is able to develop highly
potent bnAbs against HIV. Importantly, those bnAbs take multi-
ple years to develop, and virtually all have evidence of extensive
affinity maturation in GCs, as indicated by the very high levels of
somatic hypermutation in the immunoglobulin genes encoding
those BCRs (Klein et al., 2013; Liao et al., 2013; Streeck et al.,Immunity 39, 758–769,2013). Given that Tfh cells can be a
limiting factor for B cell responses (John-
ston et al., 2009; Victora et al., 2010) and
that Tfh cells are associated with better
antibody responses to simian immunode-
ficiency virus (Petrovas et al., 2012) and
chronic viral infections in mice (Boettler
et al., 2012; Fahey et al., 2011; Harker
et al., 2011), the HIV+ individuals who
make bnAbsmight have better Tfh cell re-
sponses. Testing this hypothesis required
screening a large cohort of HIV+ individ-uals. The International AIDS Vaccine Initiative (IAVI) Protocol C
program has continuously screened a large number of HIV indi-
viduals across nine sites in Africa over a period of more than 7
years in order to enroll individuals into Protocol C shortly after
they become HIV+ (blood draws are initially scheduled every
3 months), thus allowing for longitudinal study of the immune re-
sponses to HIV starting from early time points after infection. A
total of 615 individuals were enrolled at the time of the start of
this study for the examination of mechanisms of bnAb develop-
ment. A total of 1,757 serum samples from 328 HIV+ individuals,
who had each been tracked for more than 4 years, were tested
for HIV neutralizing antibodies in over 42,000 individual HIV
neutralization assays with the use of a high-throughput neutrali-
zation assay against a panel of six cross-clade viruses specif-
ically selected to represent a larger neutralization panel (Simek
et al., 2009). The majority of HIV+ individuals had antibody re-
sponses of low potency and breadth by the neutralization criteria
used (‘‘low’’), as expected (Figure 1A). The top 25 neutralizing-
antibody-scoring individuals (7%) were classified as the topOctober 17, 2013 ª2013 Elsevier Inc. 759
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Tfh Cells Correlate with HIV Antibodiesneutralizers (‘‘top’’) (Figure 1A). Top neutralizers identified from
the 6-virus cross-clade panel were subsequently confirmed
with a 36-virus cross-clade panel and showed a good correlation
(E.L. and P.P., unpublished data).
Fifteen to twenty-five percent of circulating antigen-
experienced (CD45RO+) CD4+ T cells express CXCR5 (Fig-
ure 1B)(Breitfeld et al., 2000), the primary chemokine receptor
expressed by Tfh cells. CXCR5+ cells can migrate to B cell folli-
cles because of the CXCL13 expression within B cell follicles (Vi-
nuesa and Cyster, 2011). We hypothesized that the frequency of
circulating CXCR5+CD4+ T cells might predict subsequent HIV
bnAb development in HIV+ individuals. Therefore, upon identi-
fying the top neutralizers atR3.5 years postinfection, we exam-
ined the earliest available blood sample from each of the top
neutralizers (4 months postinfection on average) and asked
whether the frequency of total CXCR5+CD4+ T cells at this time
point was predictive of the ability of some individuals to later
develop bnAbs against HIV. There was no correlation between
the capacity to develop bnAbs against HIV and total CXCR5+
CD4+ T cell percentage (top versus low, p = 0.29 [Figures 1C
and 1D]). Similarly, no correlation was found at the time of
bnAb generation, 40 months postinfection (Figure S1A, avail-
able online). However, it is unclear what the biology of total
CXCR5+CD4+ T cells in blood represents, given that these cells
have limited similarity to Tfh cells (Streeck et al., 2013). This issue
is explored in greater detail later in this study.
The vast majority of CXCR5+CD4+ T cells in blood are resting
cells. However, a very small population of activated cells (median
0.33% of CXCR5+CD4+ T cells in healthy donors) that express
ICOS and very high levels of PD-1 (PD-1+++) (Simpson et al.,
2010; Figure S1B) are also present. This phenotype is similar to
that of GC Tfh cells, which are ICOS+PD-1+++ (Crotty, 2011;
Ma et al., 2009; Rasheed et al., 2006). The majority of the blood
ICOS+PD-1+++CXCR5+CD4+ T cells were Ki67+ (Figure S1E).
Although it has been suggested that these cells are circulating
activated Tfh cells, they do not express elevated amounts of
Bcl6 or Maf (Simpson et al., 2010; data not shown), which are
central Tfh cell transcription factors required for Tfh cell differen-
tiation and function (Crotty, 2011). As an additional confounding
factor, it is reasonable to expect that some fraction of the ICOS+
PD-1+++CXCR5+ cells are not related to Tfh cells given that hu-
man CD4+ T cells readily express moderate levels of many che-
mokine receptors, including CXCR5, as activation markers for
several days after T cell receptor (TCR) stimulation (Langenkamp
et al., 2003). Currently there is not a definitive phenotypic marker
that resolves this ambiguity. Nevertheless, we examined
whether these activated ICOS+PD-1+++ cells were associated
with HIV bnAb development. ICOS+PD-1+++CXCR5+CD4+
T cell frequencies in the top and low neutralizer groups were
not statistically significant at the 4-month time point (Fig-
ure S1C) or at the time of bnAb generation (Figure S1D). HIV-spe-
cific CD4+ T cells were quantitated by intracellular cytokine stain-
ing after short peptide stimulation. Whereas interferon-g
[IFN-g]+CXCR5 HIV-specific CD4+ T cells were detectable in
many of the HIV+ individuals (25/60), no HIV-specific CXCR5+
CD4+ T cells were detected (data not shown). This might be
due to assay limitations, given that even in mice, it is difficult to
induce antigen-specific Tfh cells to secrete cytokines in conven-
tional short-term peptide-stimulation assays. Alternatively, it is760 Immunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc.plausible that HIV-specific Tfh cells are not present in blood
but remain sequestered in lymphoid tissue B cell follicles during
the ongoing viral infection while Th1 cells recirculate and patrol
infected tissues.
The failure of total CXCR5+CD4+ T cells and ICOS+PD-1+++
CXCR5+CD4+ T cells to correlate with the ability to generate
HIV bnAbs might primarily speak to our lack of understanding
of the relationship between blood CXCR5+CD4+ T cells and
lymphoid Tfh cells. These shortcomings in our understanding
impelled us to examine human blood CXCR5+CD4+ T cells in
greater depth to determine whether a proportion of quiescent
CXCR5+CD4+ T cells in blood has a clearer relationship to Tfh
cells. Despite some functional similarities between circulating
CXCR5+CD45RO+CD4+ T cells and Tfh cells (Chevalier et al.,
2011; Morita et al., 2011), the transcriptional profile of the bulk
CXCR5+CD4+ T cell population is substantially divergent from
that of active GC Tfh cells (Chevalier et al., 2011; Chtanova
et al., 2004; Rasheed et al., 2006). In addition, the functional
capacity of total blood CXCR5+CD4+ T cells to help B cells
in vitro is generally not much different from that of CXCR5 blood
cells (Chevalier et al., 2011; Pallikkuth et al., 2012; Streeck et al.,
2013). Finally, it is not clear whether any circulating CXCR5+ cells
are memory Tfh cells, given that there are limited data demon-
strating resting antigen-specific CXCR5+CD4+ T cells in humans.
In sum, the overall biology of circulating CXCR5+CD4+ T cells is
still enigmatic, and many observers have concluded that human
Tfh memory cells most likely do not exist (Craft, 2012; Ma et al.,
2012). We endeavored to clarify these issues.
Human Blood PD-1+CXCR5+ Quiescent CD4+ T Cells
To develop a deeper understanding of human blood CXCR5+
cells and their relationship to memory, we undertook a detailed
phenotypic characterization of these cells. In comparison to
GCTfh cells, human bloodCXCR5+CD4+ T cells expressed inter-
mediate levels of CXCR5 (Figure 2A). The majority of blood
CXCR5+CD4+ T cells were PD-1 (Figure 2A). As noted above,
a very small population of CXCR5+ cells (0.3%) were ICOS+
and highly expressed PD-1 (Figure S1B), at levels similar to those
of GC Tfh cells (PD-1+++). Unexpectedly, we found that a sub-
stantial population (30%) of CXCR5+ cells expressed PD-1 at
low to moderate levels (PD-1+ [Figures 2A and 2B]). Unlike the
very small population of ICOS+PD-1+++ activated cells, these
cells were Ki67 and ICOS (Figure 2A). Herein, we refer to the
population of CXCR5+ cells expressing a modest amount of
PD-1 as PD-1+CXCR5+ cells to distinguish them from the far
less abundant ICOS+ PD-1+++ activated CXCR5+ cells and to
distinguish the low PD-1 expression level from the high PD-1
level expressed by ICOS+ PD-1+++ activated CXCR5+ cells in
blood and GC Tfh cells in lymphoid tissue (Figure 2A).
PD-1 is transiently induced by TCR triggering in T cells (Keir
et al., 2008). However, PD-1 is also a component of the Tfh cell
gene expression program, regulated by Bcl6 (Kroenke et al.,
2012). The introduction of Bcl6 expression in naive blood CD4+
T cells resulted in specific upregulation of PD-1 (p = 0.01 [Figures
2C and 2D]). The observation of PD-1 expression on a subset of
circulating CXCR5+CD4+ T cells raised the question of whether
the PD-1+ cells were quiescent memory cells that stably express
PD-1 as part of a Tfh cell differentiation program. PD-1+CXCR5+
CD4+ T cells had no evidence of recent activation when
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Figure 2. Human Blood PD-1+CXCR5+CD4+ T Cells
(A) Comparison of PD-1 andCXCR5 expression between tonsil and bloodCD45RO+CD4+ T cells. Expression of the activationmarkers HLA-DR, CD38, ICOS, and
Ki67 on PD1 (filled gray), PD1+ (red line), and PD1+++ (black line) populations of CXCR5+CD4+ T cells is shown. Mean fluorescence intensity (MFI) is shown in the
upper left corner of each plot.
(B) Representative frequency of PD-1+ cells in blood CXCR5+CD45RO+CD4+ T cells.
(C and D) Bcl6 control of PD-1 expression. (C) Flow cytometric analysis of PD-1 expression on blood naive CD4+ T cells transduced with either a Bcl6 lentiviral
vector (Bcl6-LV) or a control vector (CTRL-LV). (D) MFI of PD-1 expression from cells in (E). *p = 0.01. Data from three independent experiments are shown.
(E and F) Maintenance of PD-1 expression on sorted blood PD-1+ and PD-1CXCR5+CD45RO+CD4+ T cells after 10 days of in vitro culture. (E) Flow cytometric
analysis of PD-1. (F) Quantitation of PD-1 maintenance. Data represent six or more donors per time point.
Also see Figure S2.
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Tfh Cells Correlate with HIV Antibodiesexamined directly ex vivo; compared to resting memory
PD1CXCR5+CD4+ T cells, they showed unchanged levels of
activation or proliferation markers (Ki67, HLA-DR, CD38, and
ICOS [Figure 2A]). Furthermore, we determined that activated
human CD4+ T cells expressed PD-1 for only a few days after
removal of TCR stimulation (Figure S2A). To determine whether
the resting PD-1+CXCR5+CD4+ T cells stably expressed PD-1,
we incubated sorted PD-1+ and PD-1CXCR5+CD4+ T cells for
up to 20 days ex vivo in the absence of stimulation. Strikingly,
PD-1 expression, as well as CXCR5 expression, was stable on
the surface of the cells (Figures 2E and 2F, Figure S2B, and
data not shown) (Figure S2C). Overall, these data indicate that
PD-1+CXCR5+CD4+ T cells in human blood are quiescent cells
with a stable phenotype, consistent with their potentially being
memory cells.
Blood PD-1+CXCR3–CXCR5+CD4+ T Cells and GC Tfh
Cells Share a Transcriptional Profile Signature
We hypothesized that resting blood PD-1+CXCR5+CD4+ T cells
might have more similarities than blood PD-1CXCR5+CD4+
T cells to GC Tfh cells. A first test of this hypothesis was to
perform transcriptional profiling comparing blood PD-1+
CXCR5+ cells and GC Tfh cells from tonsils, a secondary
lymphoid tissue. Previous studies showed that blood CXCR3+
CXCR5+CD4+ T cells are poor helpers of B cells (Morita et al.,
2011), which we confirmed (not shown), and we therefore sepa-
rated CXCR3 and CXCR3+ cells prior to gene expression
profiling (Figure 3A). Compared to other CXCR5+CD4+ T cell
subsets and CXCR5CD4+ T cells, blood PD-1+CXCR3
CXCR5+ cells had a distinct gene expression profile (Figure 3B).We then compared the blood CXCR5+CD4+ T cells to CD4+
T cells in tonsils as a site of active GCs. Importantly, the gene
signature of resting blood PD-1+CXCR3CXCR5+ cells was
clearly similar to that of GC Tfh cells; 94 of the top 100 genes
were concordantly regulated (Figure 3C). Furthermore, unbiased
analysis of all gene expression differences between blood PD-1+
CXCR3CXCR5+CD4+ T cells and CXCR5CD4+ T cells re-
vealed that most PD-1+CXCR3CXCR5+CD4+ T cell gene
expression changes matched the changes in GC Tfh cells
(Figure 3D).
The top-100-gene signature of blood PD-1+CXCR3CXCR5+
CD4+ T cells included a number of Tfh cell gene products,
including MAF. In both mice and humans, Maf is a critical regu-
lator of Tfh cell differentiation and function (Bauquet et al., 2009;
Ise et al., 2011; Kroenke et al., 2012). Maf was highly and selec-
tively expressed by Tfh andGCTfh cells in tonsils (Figure 3E).We
then examined resting blood PD-1+CXCR3CXCR5+CD4+
T cells and found that they expressed the highest Maf levels of
any blood CD4+ T cell population tested (p < 0.01 [Figures 3F
and 3G]). Although Bcl6 is required for Tfh cell differentiation,
higher Bcl6 expression in PD-1+CXCR3CXCR5+CD4+ T cells
compared to CXCR5 memory CD4+ T cells was not detected
(Figure S3). This is consistent with mouse memory Tfh cells
(Choi et al., 2013; Hale et al., 2013; Liu et al., 2012). The receptor
SLAMF6 (NTB-A/Ly108) regulates T cell and B cell (T:B) interac-
tions and is expressed highly on GC Tfh cells (Kageyama et al.,
2012).We observed that PD-1+CXCR3CXCR5+CD4+ T cells ex-
pressed higher levels of SLAMF6 (p < 0.001 [Figure 3H]). TIGIT
was also highly expressed on both tonsillar Tfh cells and blood
PD-1+CXCR3CXCR5+CD4+ T cells (Figure 3I). Furthermore,Immunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc. 761
581 PD1
+
CXCR3-
206 CXCR5-
Maf
TIGITTIGIT
364 CXCR5-
674 CXCR5int
2,100 CXCR5hi
259
714
A B
C
D
E GF
Maf
5
R
C
X
C
536 CXCR5-
965 CXCR5int
2,275 CXCR5hi
Maf
Tonsil Blood
Tonsil Blood
CXCR5-
CXCR5+
PD-1
PD-1
PD-1
PD-1
+CXCR3+
-CXCR3-
+CXCR3-
-CXCR3+
Blood CD4+CD45RO+
Tonsil CD4+CD45RO+
CXCR5-
GC Tfh cells
*
JH
119 552 829 242
P P
Genes upregulated in tonsil GC Tfh cells
10-1 10-1
10-6 10-6
1010-1 1010-1
Genes downregulated in tonsil GC Tfh cells
PD-1+CXCR3- CXCR5+ vs CXCR5- 1-DP)dlof( +CXCR3- CXCR5+ vs CXCR5- (fold)
S
LA
M
F6
 (M
FI
)
Pou2af1
0.0001
0.0010
0.0100
0.1000
*
*
ns *
C
X
C
R
5-
PD
-1
+C
XC
R
3-
P
D
-1
-C
X
C
R
3-
PD
-1
+C
XC
R
3+
P
D
-1
-C
X
C
R
3+
CXCR5+
I
PD
-1+
CX
CR
3-
PD
-1-
CX
CR
3-
5,000
10,000
15,000
**** PD1+
CXCR3-
CXCR5-
CXCR3
1-
D
P
13
2741
19
R
e
vit al
e
er pxe
s
noi s
0 10
0
20
0
30
0
40
0
50
0
PD-1-CXCR3+
PD-1+CXCR3+
PD-1-CXCR3-
PD-1+CXCR3-
CXCR5- **
**
**
**
Maf (MFI)
Figure 3. Blood PD-1+CXCR3–CXCR5+CD4+ T Cells Exhibit a Tfh-Cell-like Gene Expression Profile
(A–D) Four populations of human blood CXCR5+CD45RO+CD4+ T cells, defined by PD-1 and CXCR3 expression, shown in the representative plot in (A) were cell
sorted, and RNA was isolated for gene expression analysis. (B) Differentially expressed genes were hierarchically clustered, and the top 100 genes differentially
expressed by blood PD-1+CXCR3CXCR5+CD45RO+CD4+ T cells (PD-1+CXCR3) versus CXCR5CD45RO+CD4+ T cells were plotted as heatmaps for all
subsets. (C) The 100-gene signature described in (B) was then examined for expression in lymphoid tissue (tonsil) GC Tfh cells (CXCR5hiPD-1+++CD45RO+CD4+
T cells) and non-Tfh cells (CXCR5CD45RO+CD4+ T cells [CXCR5]). In (B) and (C), blue indicates low relative expression and red indicates high relative
expression. Rows represent independent subjects. (D) ‘‘Volcano’’ plots of the total gene expression data set from blood PD-1+CXCR3CXCR5+CD45RO+CD4+
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(legend continued on next page)
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Figure 4. Existence of Tetanus-Specific
Memory CD4+ TCells with the PD-1+CXCR3–
CXCR5+ Phenotype
(A) Flow cytometric analysis of CCR7 expression
on PD-1+CXCR3 (black) and PD-1CXCR3 (red)
CXCR5+CD45RO+CD4+ T cells in comparison to
CXCR5 cells (gray).
(B) CCR7 MFIs of PD-1+CXCR3, PD-1CXCR3,
CCR7+CD45RACXCR5 (TCM),CCR7CD45RA
CXCR5 (TEM), and CD45RA+ (naive) CD4+ T cells.
Individual values and medians are depicted. **p <
0.001.
(C) Tetanus-specificCD4+Tcellswere identifiedby
HLA-DRB1*0401 tetramers loaded with tetanus
peptide and enriched with magnetic beads. The
FACSplot shows a representative tetanus-specific
tetramer staining postenrichment.
(D) CXCR5 expression by tetanus-specific CD4+
T cells. Data are from seven independent HLA-
DRB1*0401+ subjects. Individual values and
means are shown.
(E) A representative flow cytometry plot of PD-1
and CXCR3 expression by tetanus-specific
CXCR5+ cells.
(F) Quantitation of PD-1+CXCR3 cells within the
CXCR5+ tetanus-specific CD4+ T cell population.
Individual values and medians are plotted.
Also see Figure S4.
Immunity
Tfh Cells Correlate with HIV Antibodiesthe transcription-factor-encoding gene POU2AF1, known to be
a regulator of CXCR5 expression in B cells, was more highly ex-
pressed in PD-1+CXCR3CXCR5+CD4+ T cells than in PD-1
CXCR5+CD4+ T cells (Figure 3J). Thus, quiescent blood PD-1+
CXCR3CXCR5+CD4+ T cells express Maf and other signature
components of the Tfh cell program.
Resting PD-1+CXCR3–CXCR5+CD4+ T Cells Are
a Population of Circulating Memory Tfh Cells
A fundamental question regarding CXCR5+CD4+ T cells in the
blood is the matter of Tfh cell memory. Although there has
been some evidence of human Tfh cell memory (Morita et al.,
2011), it is frequently argued that memory Tfh cells might not
exist (Breitfeld et al., 2000; Craft, 2012; Ma et al., 2012). All hu-
man blood CD45RO+CD4+ T cells expressing no activation
markers are conventionally inferred to be memory cells. On the
basis of this definition, PD-1+CXCR3CXCR5+CD4+ T cells are
memory cells (Figure 2A and Figure S4A). Resting CD45RO+
CD4+ T cells are usually classified as central-memory T (TCM)
or effector-memory T (TEM) cells (Sallusto et al., 1999), although
amore sophisticated subsetting ismore accurate.Whereas TEM
cells lack CCR7 and migrate to inflamed tissues, TCM cells ex-(E) Maf expression in tonsil CD45RO+CD4+ T cells.
(F) Flow cytometric analysis of Maf expression in tonsil and blood CD45RO+CD4
PD-1+CXCR3 cells; green, PD-1+CXCR3+ cells; red, PD1CXCR3 cells; cyan,
(G) Maf MFI quantitation of data in (F). Eight subjects are shown with mean and
(H) The graph displays individual SLAMF6 MFIs from 11 subjects. ****p < 0.0001
(I) TIGIT expression by flow cytometry of tonsil and blood CD45RO+CD4+ T cell
(J) Expression of POU2AF1 normalized to ACTB mRNA from six donors. Individu
Also see Figure S3.press CCR7 and circulate through secondary lymphoid organs.
Most blood CXCR5+CD4+ T cells were previously identified as
TCM cells by virtue of their positivity for CCR7 (Breitfeld et al.,
2000; Chevalier et al., 2011). We asked whether the same is
true for PD-1+CXCR3CXCR5+CD4+ T cells. We found that this
subset expressed CCR7 but at lower levels than those of
CXCR5 and PD-1CXCR5+CD4+ TCM cells (Figures 4A and
4B). To formally address whether PD-1+CXCR3CXCR5+CD4+
T cells represent memory cells, we then tested for the presence
of antigen-specific memory cells by using tetanus-specific major
histocompatibility complex (MHC) class II tetramer staining (Fig-
ure 4C and Figure S4). A substantial fraction of tetanus-specific
memory CD4+ T cells were CXCR5+ (Figure 4D). Furthermore,
tetanus-specific PD-1+CXCR3CXCR5+CD4+ T cells were pre-
sent in most donors (Figures 4E and 4F and Figure S4). Interest-
ingly, tetanus-specific memory CD4+ T cells exhibited heteroge-
neous phenotypes, consistent with the well-recognized
heterogeneity of CD4+ T cells (Streeck et al., 2013) and recently
recognized heterogeneity of memory CD8+ T cells (Newell et al.,
2012). Together, the phenotypic and MHC class II tetramer data
demonstrate that PD-1+CXCR3CXCR5+CD4+ T cells are a pop-
ulation of circulating memory Tfh cells.+ T cell populations. In blood CXCR5+ populations, colors are as follows: blue,
PD1CXCR3+ cells; and gray, CXCR5 cells.
SEM. **p < 0.001.
.
populations. Blood CXCR5+ populations are as in (F).
al values and medians are depicted. *p < 0.01. ‘‘ns’’ stands for not significant.
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Figure 5. Blood PD-1+CXCR3–CXCR5+CD4+ T Cells Display the Strongest Tfh Cell Functionality
(A and B) Blood CD4+ T cell populations (CD45RO+) were isolated by cell sorting and examined for intracellular expression of IL-21, CD40L, IL-4, IFN-g, and IL-2
by flow cytometry with or without (UNST) short in vitro stimulation (PMA and ionomycin). (A) IL-21 andCD40L expression are shown. (B) Quantitation of IL-21, IL-4,
IFN-g, and IL-2. Each point represents cells from one subject; a composite of four independent experiments is shown. Bars indicate the median.
(C) Isolated blood CD4+ T cell populations were stimulated with anti-CD3 and ICOS-L or left unstimulated (UNST) for 5 days. CXCL13 released in the supernatant
was measured by ELISA. Data are from nine donors among four independent experiments. Mean and SEM shown. ‘‘ns’’ stands for not significant.
(D) Purified blood CD4+ T cell populations were culturedwith memory B cells either in the presence of the superantigen SEB or not (UNST) for 7 days. Plasmablast
(CD20loCD38+) differentiation was analyzed by flow cytometry. Contour plots show a representative donor. The bar graphs on the right quantify B cells (CD3
cells) and plasmablasts at the end in the coculture. The bar graphs on the left show IgG and IgM production (measured by ELISA) in the T:B cocultures. Data
represent the mean and SEM from four independent experiments. *p < 0.01, **p < 0.001, ***p < 0.0005, ****p < 0.0001.
Also see Figure S5.
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Tfh Cells Correlate with HIV AntibodiesMemory PD-1+CXCR3–CXCR5+CD4+ T Cells Are Highly
Functional for B Cell Help
Tfh cells are specialized providers of help to B cells. Coexpres-
sion of IL-21, IL-4, and CXCL13 is the canonical functional signa-
ture of Tfh cells (Crotty, 2011). We compared IL-21 and IL-4
expression of blood PD-1+CXCR5+CD4+ T cells to that of other
CXCR5+CD4+ T cell subsets and non-Tfh cells. Upon stimulation
with PMA plus ionomycin, PD-1+CXCR3CXCR5+CD4+ and
PD-1+CXCR3+CXCR5+CD4+ T cells produced the highest
amounts of IL-21 (Figures 5A and 5B). PD-1+CXCR3CXCR5+764 Immunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc.CD4+ T cells expressed the most IL-4 among the CXCR5+ cells,
consistent with their higher Maf expression (Figure 5B and Fig-
ure S5A). CXCL13 expression is highly restricted. Tfh cells are
capable of producing large quantities of CXCL13 (Kim et al.,
2004; Kroenke et al., 2012; Yu et al., 2009), and blood CXCR5+
CD4+ T cells can produce CXCL13 (Chevalier et al., 2011). By
contrast, blood CXCR5CD4+ T cells did not express CXCL13
(Figure 5C). Compared to PD-1CXCR5+CD4+ T cells, PD-1+
CXCR3CXCR5+CD4+ and PD-1+CXCR3+CXCR5+CD4+ T cells
produced high levels of CXCL13 upon stimulation (Figure 5C).
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Figure 6. Highly Functional PD-1+CXCR3–CXCR5+CD4+ T Cells Are Associated with HIV bnAb Development
(A) A representative flow cytometry plot of an HIV+ donor shows the gates for the PD-1+CXCR3 population (gated on the CXCR5+CD4+ cells).
(B and C) The PD-1+CXCR3 percentage of CXCR5+CD4+ T cells in HIV and HIV+ groups at the earliest available time point (average of 4 months postinfection)
and the time of bnAb development (average of 40 months postinfection). (B) Blood samples were from the earliest available time point after HIV infection, years
before the development of bnAbs. ‘‘Top’’ indicates the top neutralizers, and ‘‘low’’ indicates the low neutralizers. Each point represents an individual donor. The
PD-1+CXCR3 percentage of CXCR5+ CD4+ T cells (gated on CXCR5+CD4+ T cells) is shown for HIV and HIV+ groups from the same samples as in Figure 1.
Mean and SEM are plotted. (C) Same as in (B), except PBMCs from HIV+ groups were tested at the time of bnAb development.
(D) Viral load (copies/ml) of the individuals in the ‘‘top’’ and ‘‘low’’ neutralizing antibody groups at the4-month time point. Bars indicate themean. ‘‘ns’’ stands for
not significant.
(E) To control for any effects of viral load (‘‘VL’’), we performed an additional analysis of the 4-month-time-point samples, excluding individuals with a low viral
load (less than 1,000 viral copies/ml, dashed line; individuals dropped for this analysis are highlighted in red in Figure S6E). The PD-1+CXCR3 percentage of
CXCR5+CD4+ T cells within the ‘‘top’’ and ‘‘low’’ neutralizing antibody groups at the4-month time point are shown for individuals with a viral load > 1,000. Mean
and SEM are plotted.
Also see Figure S6.
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Tfh Cells Correlate with HIV AntibodiesGCTfh cells in lymphoid organs have low or absent expression of
canonical cytokines of other effector CD4+ T cell types (IFN-g, IL-
17, and IL-13) (Kroenke et al., 2012; Ma et al., 2009; Yu et al.,
2009). Blood PD-1+CXCR3CXCR5+CD4+ T cells had no IFN-g
expression, whereas PD-1CXCR3+CXCR5+CD4+ and PD-1-
+CXCR3+CXCR5+CD4+ T cells expressed high levels of IFN-g
upon stimulation (Figure 5B). Interestingly, IL-2 is an inhibitor of
Tfh cell differentiation (Johnston et al., 2012) and PD-1+
CXCR3CXCR5+CD4+ T cells had the lowest percentage of
IL-2 expressors among all CD45RO+CD4+ T cells tested (Fig-
ure 5B). Thus, PD-1+CXCR3CXCR5+CD4+ T cells have a cyto-
kine profile comparable to that of active GC Tfh cells upon
restimulation.
One reason for skepticism about blood CXCR5+CD4+ T cells’
being related to Tfh cells has been that most in vitro assays have
shown that compared to blood CXCR5CD4+ T cells, bulk
CXCR5+CD4+ T cells provide only marginally better B cell help
(Chevalier et al., 2011; Pallikkuth et al., 2012; Streeck et al.,
2013). The identification of a subset of CXCR5+CD4+ T cells
that express IL-21, IL-4, and CXCL13 similarly to Tfh cells led
us to examine whether blood PD-1+CXCR3CXCR5+CD4+
T cells were functionally superior at providing help to B cells.
Importantly, in T:B cocultures, PD-1+CXCR3CXCR5+CD4+
T cells were vastly superior at inducing memory B cell differenti-
ation into plasma cells and IgG secretion (p < 0.05 and p < 0.0005
[Figure 5D]). The failure of the other T cell populations to provide
help to memory B cells was not caused by a lack of expansion or
death, given that all T cell subsets expanded and survived simi-
larly (data not shown). The majority of resting CXCR5+CD4+
T cells were PD-1 and were poor helpers of memory B cells
(Figure 5D). One interpretation is that those PD-1CXCR5+ cells
represent less polarized or differentiated Tfh cells. That interpre-tation is consistent with, and supported by, the observation that
these cells, along with PD-1+CXCR3CXCR5+ CD4+ T cells,
were competent for helping naive B cells in culture (Figure S5B).
Thus, we conclude that the highly functional PD-1+CXCR3
CXCR5+CD4+ T cells are resting memory Tfh cells with the
most polarized Tfh cell gene signature and the highest capacity
for B cell help.
Blood PD-1+CXCR3–CXCR5+CD4+ T Cells Positively
Correlate with bnAb Development in HIV+ Donors
Given that PD-1+CXCR3CXCR5+CD4+ T cells were the most
functional and polarized memory Tfh cells, we then re-evaluated
the possible association between blood CXCR5+CD4+ T cells
and the development of bnABs against HIV. We hypothesized
that memory PD-1+CXCR3CXCR5+ Tfh cells might serve as a
biomarker predicting bnAb development. Strikingly, the fre-
quency of the most functional memory Tfh cells (PD-1+
CXCR3CXCR5+ cells) at the earliest available time point
(4months postinfection) correlated with the capacity of individ-
uals to subsequently develop bnAbs against HIV many months
later (p = 0.0037 [Figures 6A and 6B]). The correlation between
PD-1+CXCR3CXCR5+ Tfh cells and bnAbs was also strong at
the time of bnAb development (p = 0.0007 [Figure 6C]). If this
population is a memory population, its percentage is expected
to be stable over time. PD-1+CXCR3CXCR5+ Tfh cell fre-
quencies for each individual were correlated at the two time
points (Figure S6A), consistent with the proposal that this is a
stable memory population. An alternative interpretation would
be that PD-1+CXCR3CXCR5+ Tfh cells represent a stable niche
but that the cells constituting this population change over time.
Subsequent statistical tests found that PD-1+CXCR3CXCR5+
cells were the only CXCR5+CD4+ T cell population thatImmunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc. 765
Immunity
Tfh Cells Correlate with HIV Antibodiescorrelated with a high-quality HIV antibody response (Figures
S1C, S1D, and S6B–S6D). Although blood CXCR3CXCR5+
cells were previously described as the blood cells possessing
the most Tfh-cell-like functional activity (Morita et al., 2011),
the proportion of CXCR3 cells among CXCR5+CD4+ T cells
did not correlate with bnAb development (Figure S6B). Addition-
ally, PD-1 by itself was not a useful biomarker, given that PD-1+
CXCR3+memory Tfh cell frequencies at either time point failed to
correlate with a capacity to develop bnAbs (Figures S6C and
S6D).
Although viral loads were not statistically significantly different
between top and low neutralizers at the earliest available time
point (Figure 6D), which was the primary time point of interest,
a statistically significant difference in viral loads did develop
over time (Figures S6E and S6G). Therefore, viral load was
controlled for as a variable. The statistical significance of the cor-
relation between PD-1+CXCR3CXCR5+ Tfh cells and bnAbs
remained effectively unchanged after correction for viral loads
(p = 0.0016, at the4-month time point postinfection [Figure 6E];
p = 0.0075 at the time of bnAb development [Figure S6H]), indi-
cating that the association between high PD-1+CXCR3CXCR5+
cell frequencies and bnAb development is an independent
parameter from viral loads. As an alternative approach, multivar-
iate analysis accounting for viral load was also performed, and
again the statistical significance of the correlation between
PD-1+CXCR3CXCR5+ cells and bnAb development was inde-
pendent of viral load (p = 0.00764 at 4 months postinfection;
p = 0.00097 at the time of bnAb development). Thus, the fre-
quency of PD-1+CXCR3CXCR5+ cells selectively correlates
with the ability to develop bnAbs against HIV.
Together, these data provide evidence that PD-1+CXCR3
CXCR5+CD4+ T cells are a human memory CD4+ T cell type
with high Tfh cell functionality. Furthermore, the ability of rare
HIV-infected individuals to make bnAbs against HIV is associ-
ated with the presence of these PD-1+CXCR3CXCR5+ highly
functional memory Tfh cells, supporting the concept that
enhanced T cell help to B cells is most likely a critical component
of any candidate HIV vaccine designed to elicit potent bnAbs
against HIV.
DISCUSSION
Whereas most human vaccines, and many new candidate vac-
cines, for major infectious killers of humans are dependent on
quality antibody responses, our understanding of how Tfh cells
support and impact that process in humans is just developing
(Crotty, 2011; Streeck et al., 2013). Here, we identified a popula-
tion of highly functional circulatingmemory Tfh cells with a strong
transcriptional resemblance to GC Tfh cells. Quiescent PD-1+
CXCR3CXCR5+CD4+ T cells were marked by the expression
of a number of Tfh-cell-related molecules, including Maf, TIGIT,
POU2AF1, Slamf6, and PD-1. Besides playing a pivotal role in
the differentiation and function of Tfh cells, Maf also regulates
IL-21 and IL-4. We did not detect elevated Bcl6 in memory
PD-1+CXCR3CXCR5+CD4+ T cells. Bcl6 expression in murine
memory Tfh cells was recently found to be downregulated and
not expressed higher than in resting non-Tfh memory cells
(Choi et al., 2013; Hale et al., 2013; Liu et al., 2012). The lack of
elevated Bcl6 suggests that some aspects of Tfh cells are main-766 Immunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc.tained by low Bcl6 levels or are initiated by Bcl6 expression and
are sustained by other facets of the Tfh cell program when Bcl6
levels decrease in quiescent memory cells.
Whether circulating CXCR5+ cells are thememory counterpart
of Tfh cells has been controversial. We directly identified mem-
ory Tfh cells by tetanus-specific MHC class II tetramer staining.
PD-1+CXCR3CXCR5+CD4+ T cells can be defined as TCMcells
by virtue of CCR7 expression. Although active Tfh cells are
located in secondary lymphoid organs, it is not surprising to
find memory Tfh cells in the blood. Indeed, it is reasonable to as-
sume that similarly to other CD4+ TCM cells and memory B cells,
memory Tfh cells regularly recirculate to distribute themselves
throughout secondary lymphoid tissues. It is intriguing that,
although positive, the PD-1+CXCR3CXCR5+CD4+ T cells ex-
pressed lower levels of CCR7 than did PD-1CXCR5+CD4+
T cells. A coordinated increase in CXCR5 and decrease in
CCR7 is important for CD4+ T cell localization to B cell follicles
(Haynes et al., 2007), and lower levels of CCR7 might allow for
a deeper migration into B cell follicles in vivo.
In our study, the PD-1+CXCR3CXCR5+CD4+ T cells emerged
as the cells with the highest functional ability to help B cells. All of
the CXCR5+ cells were capable of upregulating CD40L and pro-
ducing IL-21 and CXCL13 to some degree. Strikingly, the PD-1+
CXCR3CXCR5+CD4+ T cells were the only ones capable of
supporting efficient antibody responses by memory B cells
in vitro. The PD-1+CXCR3CXCR5+CD4+ T cells appeared to
be the most differentiated and highly functional memory Tfh
cells, in line with the idea that optimal memory Tfh cells would
be able to efficiently provide help to both naive and memory B
cells. Nevertheless, we do not exclude that the other CXCR5+
CD4+ T cells are part of the memory Tfh cell family. One possibil-
ity is that these cells might be less polarized Tfh cell memory pre-
cursors that require further stimuli to complete their differentia-
tion process. The CXCR3+ cells might have been exposed to
excessive Th1 stimuli, diverting their Tfh cell differentiation.
A recent study by Bentebibel and colleagues has found that a
small population of activated ICOS+CXCR3+CXCR5+ cells tran-
siently appear in human blood after influenza vaccination and
that these cells correlate with influenza antibody titers (Bentebi-
bel et al., 2013). That observation was unexpected, given that
Morita and colleagues demonstrated that CXCR3+CXCR5+ cells
are the worst CXCR5+CD4+ T cells at helping B cells (Morita
et al., 2011), and we have confirmed that finding here. The
CD4+ T cells arising after influenza vaccination are transient
effector cells displaying an activated phenotype, including
expression of ICOS and Ki67, and their lineage is unclear, given
that many activated human CD4+ T cells can express CXCR5
and other chemokine receptors transiently. In contrast, our study
focused on resting cells. Here, we have now demonstrated that
quiescent blood CXCR5+CD4+ T cells (lacking ICOS and other
activation markers), including the PD-1+CXCR3CXCR5+ cells
that were the focus of this study, are a memory cell population.
Notably, the influenza vaccine is notorious for being the least
protective vaccine among vaccines commonly used in the
United States, even when the influenza strain is well matched
(CDC, 2013), and the influenza vaccine also suffers from an un-
usually short duration of protection after immunization (CDC,
2011). Therefore, the very weak B cell help provided by CXCR3+
CXCR5+CD4+ T cells shown both here and by Morita and
Immunity
Tfh Cells Correlate with HIV Antibodiescolleagues (Morita et al., 2011) suggests that the currently avail-
able influenza vaccines might generate poor antibody protection
precisely because they elicit CXCR3+CXCR5+ cells. We specu-
late that an influenza vaccine promoting the generation of highly
functional PD-1+CXCR3CXCR5+ memory Tfh cells described
herein would result in better antibody responses and efficacious
protection against influenza.
Surrogate cell populations in blood are essential as clinical
study markers. Although a direct analysis of bona fide active
GC Tfh cells from lymph nodes of bnAb+ individuals would
have provided valuable information, this was not feasible. There-
fore, the study of the relationship between Tfh cells and HIV
bnAb development relied upon the definition of highly functional
memory Tfh cells in the blood. We identified PD-1+CXCR3
CXCR5+CD4+ T cells as the blood population with the most pro-
nounced phenotypic and functional hallmarks of bona fide Tfh
cells. Remarkably, PD-1+CXCR3CXCR5+CD4+ T cells were
the only population of blood CXCR5+ cells in HIV+ individuals
to positively correlate with the generation of bnAbs against HIV
in this study. We focused our analysis on cell frequency, instead
of absolute numbers, in order to minimize unknown confounding
factors in HIV+ individuals and to concentrate on biases in the dif-
ferentiation of different subtypes of memory Tfh cells. However,
as with most human immunology studies, we do not know how
directly the blood frequencies relate to cell frequencies in the
lymph nodes and spleen, the sites of GCs and T:B interactions.
We interpret the increased frequency of optimal circulating
memory Tfh cells to be a biomarker of the ability to generate
strong Tfh cell responses necessary to drive high levels of
somatic hypermutation found in HIV bnAbs. Future studies
directly interrogatingmemory Tfh cells in lymphoid tissues would
be of great value.
Previously, clinical and viral parameters have been associated
with HIV bnAb production (Hessell and Haigwood, 2012).
Those previous findings support a model in which antigen load
and HIV envelope diversity are important components of the
evolution of bnAbs. It is likely that antigen load and a recursive
process of antibody mutation and virus escape (Richman et al.,
2003) provide the basis for the process of antibody epitope
honing to the most conserved HIV envelope epitopes (Liao
et al., 2013). However, because most individuals with high viral
loads do not develop bnAb responses, the limiting factor (or
factors) is clearly something other than viral load, and it is logical
to consider host immune factors. Although it is reasonable to
assume that multiple factors play important roles in the process
of HIV bnAb development, our data show that individuals who
make a bnAb response preferentially have higher percentages
of the highly functional circulating PD-1+CXCR3CXCR5+
memory Tfh cells. Consistent with the fact that both antigen
and Tfh cells are instrumental parts of the GC response, it is
logical that both factors are positively associated with the end
product—a highly mutated antibody capable of neutralizing
most HIV strains.
Here, we have demonstrated that highly functional memory
Tfh cells are present in human blood and that these cells corre-
late with a clinically important outcome: the development of
potent bnAbs against HIV. These findings might facilitate rational
vaccine design against HIV and other pathogens. Although it is
conceivable that an antibody-dependent HIV vaccine ispossible, given the discovery of bnAb+ individuals, the path to
eliciting such antibodies by vaccination is unclear (Burton
et al., 2012; McMichael and Haynes, 2012). HIV bnAbs are highly
affinity maturated, well above the average affinity maturation
observed in human memory B cells and well beyond the amount
of affinity maturation elicited by current human vaccines (Streeck
et al., 2013). Although it was hypothetically possible that Tfh cells
are important for bnAb development, the results reported here
are evidence of a positive association between a Tfh cell popu-
lation and bnAb development. These results provide an encour-
aging indication that generating better Tfh cell responses and Tfh
cell memorymight be a fruitful vaccine strategy for enhancing the
quality of antibody responses against HIV sufficiently to accom-
plish the generation of HIV bnAbs in the context of a candidate
vaccine employing appropriate HIV Env trimer antigens or HIV
Env trimer expression. Furthermore, characterization of PD-1-
+CXCR3CXCR5+CD4+ T cells as the most highly functional
memory Tfh cells indicates that candidate HIV vaccines should
attempt to preferentially elicit these cells for maximal B cell
help and affinity maturation after immunization. In addition, PD-
1+CXCR3CXCR5+ memory CD4+ T cells are present in human
peripheral blood and therefore can be readily quantified. Finally,
the relevance of these results is unlikely to be restricted to HIV
vaccine development given that protective immunity to a range
of pathogens for which the human immune system has difficulty
developing high-quality antibody responses might be limited by
the quality of the Tfh cell response and the resultant capacity to
generate highly affinity-matured antibody responses.
EXPERIMENTAL PROCEDURES
Human Samples
Fresh blood samples (for Figures 2, 3, 4, and 5) from healthy donors were ob-
tained from the La Jolla Institute for Allergy and Immunology (LJI) blood donor
program. Informed consent was obtained from all donors. Peripheral-blood
mononuclear cells (PBMCs) were isolated from blood by density-gradient
centrifugation using Histopaque-1077 (Sigma-Aldrich). Fresh human tonsils
were obtained from the National Disease Resource Interchange. Tonsil prep-
aration was previously described (Kroenke et al., 2012). Details on Protocol C
donor recruitment and testing are described in the Supplemental Experimental
Procedures. All protocols were approved by LJI and National Disease
Resource Interchange institutional review boards.
Flow Cytometry and Cell Sorting
For the intranuclear staining, cells were treated with the FoxP3 Fixation/
Permeabilization Kit (eBioscience) and stained in permeabilization buffer
(eBioscience). For surface staining, primary staining panels used for pheno-
typic analysis or for cell sorting are described in Tables S1 and S2. See Sup-
plemental Experimental Procedures for detailed descriptions.
Gene Expression Microarrays
Blood CD4+ T cells were enriched by magnetic-bead isolation (CD4+ T Cell
Isolation Kit II, Miltenyi Biotec). After enrichment, CD14CD16CD19
CD8CD4+CD45RA cells were sorted by fluorescence-activated cell sorting
(FACS) into the following five populations: CXCR5, PD1+CXCR3CXCR5+,
PD1+CXCR3+CXCR5+, PD1CXCR3CXCR5+, and PD1CXCR3+CXCR5+.
Cells were directly sorted in buffer RLT for RNA extraction. Sorting of tonsil
GC Tfh (CXCR5hi) cells and Tfh (CXCR5int) cells was previously described
(Kroenke et al., 2012). RNA was isolated with the RNeasy Micro Kit (QIAGEN).
The quantity and quality of the RNA were confirmed with a NanoDrop 2000c
(Thermo Fisher Scientific) and an Experion Electrophoresis System
(Bio-Rad). Samples (20 ng) were amplified with Illumina MessageAmp II
aRNA Amplification Kits (Ambion), hybridized to HumanHT-12_V4 BeadChipsImmunity 39, 758–769, October 17, 2013 ª2013 Elsevier Inc. 767
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Tfh Cells Correlate with HIV Antibodies(Illumina), and quantified with Genome Studio (Illumina). Normalized data
(heatmap of blood cells) or raw data (heatmap of tonsil cells and Volcano
plot) were analyzed with the GenePattern software suite.
T:B Coculture Assay
CD4+ T cells were isolated from fresh PBMCs by magnetic-bead negative se-
lection with the CD4+ T Cell Isolation Kit II (Miltenyi Biotec). The CD19
CD14CD8CD4+CD45RO+ cells were sorted by FACS into CXCR5, PD1+
CXCR3CXCR5+, PD1+CXCR3+CXCR5+, PD1CXCR3+CXCR5+, and PD1
CXCR3 CXCR5+ subpopulations. B cells were isolated from fresh PBMCs
by CD19 magnetic-bead positive selection (Miltenyi Biotec). Memory B cells
were then sorted as CD3CD14CD4CD19+IgDCD27+CD38 cells. Mem-
ory B cells (3 3 104 cells/well) were cocultured with the different T cell popu-
lations (3 3 104 cells/well) in the presence of staphylococcal enterotoxin B
(SEB, 100ng/ml, Toxin Technology) in AIM-V medium (Life Technologies). B
cell number, phenotype, and Ig concentrations in the supernatants were
measured after 7 days.
Statistical Analysis
A two-tailed Mann-Whitney test was used for evaluating differences in the
populations of the HIV clinical cohorts shown in Figures 1 and 6. The Mann-
Whitney nonparametric rank-comparison statistical test is optimal for analysis
of the clinical cohort because it does not assume a normal distribution of the
data, a standard approach with human samples. Corrections for multiple tests
were not applied because each test was based on a specific hypothesis spec-
ified in advance. Covariance of PD-1+CXCR3CXCR5+ Tfh cells and viral load
was evaluated with the ANCOVA multivariate statistical test (VassarStats).
Prism 5.0 (GraphPad) was used for all other data statistical analyses. The sta-
tistical analyses of the biological phenotypes and functionality of CXCR5+
CD4+ T cell populations from healthy controls (Figures 2, 3, 4, and 5) were
done with two-tailed paired t tests. The paired t test is the best statistical
test in this case because of the direct comparison of populations within do-
nors. Independent experiments were repeated several times with controls.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession numbers
GSE50390 (blood CD4+ T cells) and GSE50391 (tonsil CD4+ T cells) and
together under the GEO SuperSeries accession number GSE50392.
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